Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Tuberculosis

Free Subscription Articles published in J Antimicrob Chemother Retrieve available abstracts of 33 articles: HTML format Text format

Single Articles

October 2018
1. DOAN TN, Fox GJ, Meehan MT, Scott N, et al
   Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
   J Antimicrob Chemother. 2018 Oct 5. pii: 5116208. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   July 2018
2. WHITFIELD MG, Warren RM, Mathys V, Scott L, et al
   The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis.
   J Antimicrob Chemother. 2018 Jul 5. pii: 5049577. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   March 2018
3. CANEZIN PH, Caleffi-Ferracioli KR, Scodro RBL, Siqueira VLD, et al
   Intramacrophage Mycobacterium tuberculosis efflux pump gene regulation after rifampicin and verapamil exposure.
   J Antimicrob Chemother. 2018 Mar 22. pii: 4951545. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   January 2018
4. DOOKIE N, Rambaran S, Padayatchi N, Mahomed S, et al
   Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care.
   J Antimicrob Chemother. 2018 Jan 19. pii: 4817621. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   December 2017
5. LIU Y, Pertinez H, Ortega-Muro F, Alameda-Martin L, et al
   Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria.
   J Antimicrob Chemother. 2017 Dec 12. pii: 4735127. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   October 2017
6. VYAZOVAYA A, Levina K, Zhuravlev V, Viiklepp P, et al
   Emerging resistant clones of Mycobacterium tuberculosis in a spatiotemporal context.
   J Antimicrob Chemother. 2017 Oct 30. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
7. YEW WW, Liang D, Chan DP, Shi W, et al
   Molecular mechanisms of clofazimine resistance in Mycobacterium tuberculosis.
   J Antimicrob Chemother. 2017;72:2943-2944.
   PubMed     Text format    
   
   
   September 2017
8. CHEN J, Zhang S, Cui P, Shi W, et al
   Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis.
   J Antimicrob Chemother. 2017 Sep 12. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   August 2017
9. SVENSSON RJ, Gillespie SH, Simonsson USH
   Improved power for TB Phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods.
   J Antimicrob Chemother. 2017;72:2311-2319.
   PubMed     Text format     Abstract available
   
   
   June 2017
10. KAUSHIK A, Ammerman NC, Tasneen R, Story-Roller E, et al
    In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2017 Jun 1. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
11. YEW WW, Leung CC, Zhang Y
    Oxidative stress and TB outcomes in patients with diabetes mellitus?
    J Antimicrob Chemother. 2017;72:1552-1555.
    PubMed     Text format     Abstract available
    
    
    May 2017
12. MAITRE T, Petitjean G, Chauffour A, Bernard C, et al
    Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?
    J Antimicrob Chemother. 2017 May 23. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
13. NAIDOO A, Chirehwa M, McIlleron H, Naidoo K, et al
    Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.
    J Antimicrob Chemother. 2017;72:1441-1449.
    PubMed     Text format     Abstract available
    
    
    April 2017
14. ZIMENKOV DV, Nosova EY, Kulagina EV, Antonova OV, et al
    Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.
    J Antimicrob Chemother. 2017 Apr 6. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
15. SEKAGGYA-WILTSHIRE C, von Braun A, Scherrer AU, Manabe YC, et al
    Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.
    J Antimicrob Chemother. 2017;72:1172-1177.
    PubMed     Text format     Abstract available
    
    
    March 2017
16. GURUMURTHY M, Verma R, Naftalin CM, Hee KH, et al
    Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial.
    J Antimicrob Chemother. 2017 Mar 18. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
17. JAGANATH D, Schaaf HS, Donald PR
    Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.
    J Antimicrob Chemother. 2017 Mar 9. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
18. VILLELLAS C, Coeck N, Meehan CJ, Lounis N, et al
    Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.
    J Antimicrob Chemother. 2017;72:684-690.
    PubMed     Text format     Abstract available
    
    
    February 2017
19. CAVANAUGH JS, Jou R, Wu MH, Dalton T, et al
    Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
    J Antimicrob Chemother. 2017 Feb 20. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
20. CHOLO MC, Mothiba MT, Fourie B, Anderson R, et al
    Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline.
    J Antimicrob Chemother. 2017;72:338-353.
    PubMed     Text format     Abstract available
    
    
    January 2017
21. GOTHAM D, Fortunak J, Pozniak A, Khoo S, et al
    Estimated generic prices for novel treatments for drug-resistant tuberculosis.
    J Antimicrob Chemother. 2017 Jan 10. pii: dkw522. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    December 2016
22. ROBERTSON GT, Scherman MS, Bruhn DF, Liu J, et al
    Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw467. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
23. NAGU TJ, Aboud S, Matee MI, Maeurer MJ, et al
    Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre study.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw503. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    October 2016
24. AMMERMAN NC, Swanson RV, Tapley A, Moodley C, et al
    Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available
    
    
    September 2016
25. HOFFMANN H, Borroni E, Schena E, Nedialkova L, et al
    Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC MGIT 960 system-authors' response.
    J Antimicrob Chemother. 2016.
    PubMed     Text format    
    
    
    June 2016
26. DUTTA NK, Bruiners N, Pinn ML, Zimmerman MD, et al
    Statin adjunctive therapy shortens the duration of TB treatment in mice.
    J Antimicrob Chemother. 2016;71:1570-7.
    PubMed     Text format     Abstract available
    
    
    May 2016
27. HENNIG S, Svensson EM, Niebecker R, Fourie PB, et al
    Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs.
    J Antimicrob Chemother. 2016;71:1330-40.
    PubMed     Text format     Abstract available
    
    
    
28. COJUTTI P, Duranti S, Isola M, Baraldo M, et al
    Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB?
    J Antimicrob Chemother. 2016;71:1323-9.
    PubMed     Text format     Abstract available
    
    
    April 2016
29. PANDIE M, Wiesner L, McIlleron H, Hughes J, et al
    Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.
    J Antimicrob Chemother. 2016;71:1037-40.
    PubMed     Text format     Abstract available
    
    
    
30. OLARU ID, Lange C, Heyckendorf J
    Personalized medicine for patients with MDR-TB.
    J Antimicrob Chemother. 2016;71:852-5.
    PubMed     Text format     Abstract available
    
    
    March 2016
31. SAKTIAWATI AM, Sturkenboom MG, Stienstra Y, Subronto YW, et al
    Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.
    J Antimicrob Chemother. 2016;71:703-10.
    PubMed     Text format     Abstract available
    
    
    
32. RIEU R, Chang C, Collin SM, Fazekas J, et al
    Time to detection in liquid culture of sputum in pulmonary MDR-TB does not predict culture conversion for early discharge.
    J Antimicrob Chemother. 2016;71:803-6.
    PubMed     Text format     Abstract available
    
    
    February 2016
33. RIGOUTS L, Coeck N, Gumusboga M, de Rijk WB, et al
    Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.
    J Antimicrob Chemother. 2016;71:314-23.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: